The investigators closed their report by explaining that while therapies like tenapanor and SNF472 have shown promise, and ...

Neovascular age-related macular degeneration (nAMD) is a leading cause of irreversible vision impairment in adults, affecting ...

Advanced disease progression occurred less often with vutrisiran than placebo in both the overall population (8.0% vs 10.7%) and monotherapy subgroup (8.2% vs 11.1%). Transition to NYHA class IV was ...

Why Medicaid-covered kids struggle to see pediatricians: low reimbursement and practice deserts in low-income ZIP codes ...

When a woman is diagnosed with breast cancer, the clinical machinery swings into motion: imaging, staging, oncology referrals ...

Susan Cantrell, CEO of AMCP, explained in an interview with The American Journal of Managed Care® ( AJMC®) that the ...

Tirzepatide (Mounjaro; Eli Lilly), a dual glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide ...

Nancy L. Lewis, MD, MBS, FACP, reflects on the career journey that led her to her new role as chief scientific officer (CSO) ...

Among the most striking findings, 86.1% of patients treated with bimekizumab were completely flare-free across the entire ...

Clinically significant insomnia, elevated OSA risk, and insufficient sleep duration were markedly higher in rural Appalachian ...

These findings, reported in 2 posters presented at the 2026 American Academy of Dermatology Annual Meeting, highlight ...

When asked about behavioral support, 56% of employed adults said they would self-pay for a GLP-1 if their employer offered a ...